Arthritis Rheumatol. 2022;74:1648–1659 doi: 10.1002/art.42250
Large, population-based, real-world cohort of study in patients with RA finds tofacitinib not to be associated with an increased risk of malignancies, in comparison to TNFi agents, although a numerically increased risk of malignancies was observed in older patients with risk factors for cardiovascular disease.
Following findings from the ‘ORAL Surveillance’ trial, indicating that there is an increased risk for the development of malignancies with tofacitinib therapy when compared to treatment with TNFi, Khosrow-Khavar, et al. carried out a multi-database, population-based study to further examine the risk of malignancies with tofacitinib, in representative RA patients treated in a real-world clinical setting.